12:00 AM
 | 
Oct 18, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Actonel risedronate: Phase III data; under FDA review; marketed to treat Paget's disease

Researchers published in the Journal of the American Medical Association data from Procter & Gamble and co-development and co-marketing partner Hoechst Marion Roussel's 2,458-patient Phase III study comparing 2.5 mg or 5 mg Actonel per...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >